{"id":506225,"date":"2026-06-18T14:44:10","date_gmt":"2026-06-18T14:44:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/506225\/"},"modified":"2026-06-18T14:44:10","modified_gmt":"2026-06-18T14:44:10","slug":"long-term-data-show-continued-efficacy-and-safety-of-sparsentan-in-fsgs","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/506225\/","title":{"rendered":"Long-term Data Show Continued Efficacy and Safety of Sparsentan in FSGS"},"content":{"rendered":"<p>Patients with focal segmental glomerulosclerosis (FSGS) are at increased risk of progression to kidney failure within 10 years of diagnosis. Studies have shown an association between lowering proteinuria across a range of thresholds and a reduction in the risk for kidney failure.<\/p>\n<p>The ongoing phase 3 DUPLEX trial was designed to assess the efficacy and safety of sparsentan in patients with FSGS. During a session at the 63rd European Renal Association Congress in Glasgow, Scotland, Sian Griffin, MBBC, PhD, and colleagues presented long-term open-label extension (OLE) data from the trial.<\/p>\n<p>Participants in the DUPLEX study who received sparsentan in the double-blind period and continued in the OLE, as well as those who switched from irbesartan (IRB) and initiated sparsentan in the double-blind period and remained on sparsentan in the OLE, maintained durable reductions in proteinuria and achieved clinically meaningful low proteinuria thresholds over time, including complete remission.<\/p>\n<p>During the OLE, patients who remained on sparsentan maintained durable reductions in proteinuria and continued to achieve clinically meaningful low thresholds of proteinuria. At any time across the double-blind or OLE period, 37.5% achieved complete remission (CR), defined as urine protein-to-creatinine ratio (UPCR) less than 0.3 g\/g, and 87.5% achieved partial remission (UPCR &lt;1.5 g\/g). Participants who switched from IRB to sparsentan in the OLE experienced rapid and sustained reductions in proteinuria, 28.9% achieved CR at any time across the double-blind or OLE period, and 74.6% achieved partial remission.<\/p>\n<p>Sparsentan was generally well tolerated during the OLE follow-up period, with a safety profile consistent with earlier findings and low rates of treatment discontinuation related to treatment-emergent adverse events.<\/p>\n<p>Jula Inrig, MD, chief medical officer of Travere Therapeutics, said in a press release, \u201cThese long-term open-label extension data continue to reinforce the meaningful and sustained impact [sparsentan] can have for people living with FSGS without nephrotic syndrome. Patients experienced clinically meaningful reductions in proteinuria after initiating [sparsentan], whether treatment began during the double-blind period or after transition from [IRB] in the open-label extension. The continued response observed over approximately 5 years, including 3 years in the open-label extension, further validates the benefit of [sparsentan] and adds to a growing body of evidence supporting its role as foundational care in FSGS.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Patients with focal segmental glomerulosclerosis (FSGS) are at increased risk of progression to kidney failure within 10 years&hellip;\n","protected":false},"author":2,"featured_media":506226,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-506225","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/506225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=506225"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/506225\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/506226"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=506225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=506225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=506225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}